Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

356.98 +1.45 (+0.41%)

Streaming Delayed Price Updated: 9:49 AM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast ↗

July 31, 2025

Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises.

Via Benzinga

Topics Earnings

Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗

July 31, 2025

Via Benzinga

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

July 31, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

July 23, 2025

Via Benzinga

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

July 21, 2025

Via Benzinga

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

July 21, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

July 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts ↗

July 16, 2025

Via Benzinga

Alnylam Pharma Stock Outlook: Is ALNY Topping Out? ↗

July 01, 2025

Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics.

Via Benzinga

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts ↗

June 30, 2025

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

June 30, 2025

Via Benzinga

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗

June 26, 2025

Via Benzinga

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

June 18, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗

June 16, 2025

Via Benzinga

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

June 12, 2025

Via Benzinga

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025

From Instil Bio

Via GlobeNewswire

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

June 09, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case ↗

June 05, 2025

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Via Benzinga

Topics Intellectual Property

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

May 26, 2025

Via Benzinga

3 High-Flying Stocks That Could Soar Even More ↗

May 24, 2025

Via The Motley Fool

Alnylam Issues 2024 Corporate Responsibility Report

May 20, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 12, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

May 08, 2025

Via Benzinga

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 05, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk ↗

May 02, 2025

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.

Via Benzinga

Topics World Trade

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 02, 2025

Via Benzinga

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

May 01, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.